Combining conjugation chemistry and MR technology to overcome tumour heterogeneity and increasing therapy efficacy in radionuclide therapy

Using the expertise in a multidisciplinary team and combining efforts using new MRI technology with targeted radionuclide therapy, we aim to develop a methodology for increasing the therapeutic efficacy with radiochemistry to create more homogenous absorbed dose distributions in tumour tissue thereby increasing the therapeutic efficacy.
In radionuclide therapy, a heterogeneous distribution of targeting agents in the tumour causes a suboptimal distribution of absorbed dose with poor therapeutic efficacy. The purpose of this project is to evaluate if different conjugation strategies can improve the heterogeneous distribution of radiolabeled targeting agents in the tumors hence improving therapy, efficacy. Furthermore, as precision medicine is a pillar stone in cancer therapy there is an unmet need for patient stratification and therapy evaluation. The current form of therapy evaluation in the clinic of targeting agents are anatomical imaging, 18FDG-PET or invasive biopsy. These methods are non-informative of real time receptors expression and tumour microstructure. In this study we will use novel non-invasive MRI-based biomarkers to monitor physiological parameters for homogenous distribution. The primary goal is to develop this new methodology for prostate cancer (PCa). Our goal is to develop a theragnostic non-invasive platform for therapy and imaging